ERBB2 and neoplasm: Tumor resistance to FGFRis is identified in multiple tumor types and are mostly related to activation of different signaling pathways including MET, Eph3B, ERBB2/3 or EGFR and/or activation of intracellular signaling pathways without tyrosine kinase receptor dependence (42).